vintage champagne socialist 🇺🇦 🏳️‍🌈

  • 27 Posts
  • 160 Comments
Joined 1 year ago
cake
Cake day: June 9th, 2023

help-circle




  • But you are still forgetting the main point. EMA allows the nations under it to move drugs around

    Not during shortages, the Single Market doesn’t force anyone to share anything

    If ou need a drug in one nation. That your helth service dosent want to provide. You can buy it yourself and import from another EU nation. As we could in 2019.

    Without a prescription?

    Now you cabnnot unless MHRA also covers it. So any drug created since 2020. Requires 2x the paperwork to even give you the option to buy.

    The MHRA did the vast majority of the certification for the EMA…and the UK is still using the EU law and EMA to approve most medications

    But, while the UK still relies on ema decisions, it has approved new cancer drugs more quickly

    Brexit was also hailed as an opportunity for the UK to innovate alongside international partners, and here the UK has made progress. A number of schemes to fast-track promising drugs have borne fruit: in 2021, four innovative new cancer drugs were approved in the UK via an international scheme, Project Orbis, coordinated in the US with other non-EU partners. Additionally, the national Early Access to Medicines Scheme, which allows UK medics to prescribe before formal MHRA approval, saw another four medicines fast tracked for patients.

    https://www.imperial.ac.uk/business-school/ib-knowledge/health/post-brexit-medicine-approvals-what-we-know

    And the UK has the 7th largest share of the global pharma market. Do pharma suppliers not bother with approvals in Japan or Canada either?


  • The population of the EU is approx 448m (jan 1 23) the UK 67.7+m (23 no date) so the simple fact is where companies have a choice to sell. They have 6.5x the potential customers for exactly the same amount of documentation as the UK.

    It’s not that simple though, the supposed panacea that is the single market is just that. You can’t just sell into the single market, you need sales and ops for each country.

    In Germany, around 90% of medicines that obtain marketing authorisation from the European Medicines Agency (EMA) are available to citizens while in Lithuania, for example, it is only 20% of the approved drugs.

    Another major problem is the length of time it takes for a drug to appear on the national market after EU registration.

    Germany is again the leader in this respect, with a waiting time of around 100 days. At the other end of the spectrum is Romania, where the procedure can take up to 900 days, or 2.5 years. In the Czech Republic, the average time for the whole process is around 1.5 years.

    https://www.euractiv.com/section/health-consumers/news/a-single-market-for-medicines-would-be-no-panacea-pharma-companies-warn/